精神分裂症患者背外侧前额叶皮质谷氨酸水平的1H-MRS荟萃分析
该研究对精神分裂症患者背外侧前额叶皮质谷氨酸的病例对照1H-MRS研究进行荟萃分析,共纳入429例患者和365例对照。总体未发现组间差异,但敏感性分析显示用药状态影响效应:未用药患者谷氨酸升高且变异度降低,用药患者变异度升高。结论提示评估代谢物水平时需注意药物混杂。
要点
- 精神分裂症患者与对照的背外侧前额叶谷氨酸总体无显著差异。
- 未用药患者谷氨酸升高(d=0.46),且变异系数比降低。
- 用药患者变异系数比升高,提示药物状态影响代谢物评估。
核心结论
- 总体未发现精神分裂症患者与对照的背外侧前额叶谷氨酸差异。
- 未用药患者谷氨酸升高且变异度降低,可能反映稳态机制。
- 评估临床样本代谢物水平时需注意药物混杂。
研究设计与样本
- 对高场1H-MRS病例对照研究进行荟萃分析,检索PubMed。
- 定量分析纳入429例患者和365例对照。
- 采用固定和随机效应模型,计算Cohen's d和方差比。
主要发现
- 总体组间差异无统计学意义(d=0.03,95%CI -0.20至0.26,p=0.78)。
临床怎么用
- 解读精神分裂症患者前额叶谷氨酸水平时应考虑抗精神病药物状态。
- 未用药患者可能呈现谷氨酸升高和变异度降低的模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, there is no systematic overview of glutamate in the dorsolateral prefrontal cortex (DLPFC) of patients with schizophrenia. Here, we meta-analyzed case-control studies of high-field proton magnetic resonance spectroscopy (1H-MRS) investigating glutamate in DLPFC. Additionally, we estimated variance ratios to investigate homo/heterogeneity. METHODS: Preregistration of the study was performed on September 20, 2019. The predefined literature search on PubMed comprised articles with search terms (magnetic resonance spectroscopy OR MRS) AND (glutamate OR glut∗ OR GLX) AND (schizophrenia OR psychosis OR schizophren∗). Meta-analyses with a fixed- and random-effects model with inverse variance method, DerSimonian-Laird estimator for τ2, and Cohen's d were calculated. For differences in variability, we calculated a random-effects model for measures of variance ratios. The primary study outcome was the difference in glutamate in the DLPFC in cases versus controls. Secondary outcomes were differences in variability. RESULTS: The quantitative analysis comprised 429 cases and 365 controls. Overall, we found no group difference (d = 0.03 [95% confidence interval (CI), -0.20 to 0.26], z = 0.28, p = .78). Sensitivity analysis revealed an effect for medication status (Q = 8.35, p = .039), i.e., increased glutamate in antipsychotic-naïve patients (d = 0.46 [95% CI, 0.08 to 0.84], z = 2.37, p = .018). Concerning variance ratios, we found an effect of medication status (Q = 16.95, p < .001) due to lower coefficient of variation ratio (CVR) in medication-naïve patients (logCVR = -0.49 [95% CI, -0.78 to -0.20], z = -3.33, p < .001). In studies with medicated patients, we found higher CVR (logCVR = 0.22 [95% CI, 0.06 to 0.39], z = 2.67; p = .008). CONCLUSIONS: We carefully interpret the higher levels and lower variability in cortical glutamate in antipsychotic-naïve patients as a possible key factor resulting from a putative allostatic mechanism. We conclude that care has to be taken when evaluating metabolite levels in clinical samples in which medication might confound findings.
引用
- Kaminski J, Mascarell-Maricic L, Fukuda Y, et al. Glutamate in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-analysis of 1H-Magnetic Resonance Spectroscopy Studies. Biol Psychiatry. 2020. PMID: 33129486. doi:10.1016/j.biopsych.2020.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。